Webinar

China’s Biotech & Biopharma Capital Market Reset

By submitting this information, I agree to the privacy policy and to learn more about products and services from Bloomberg.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Following all-time highs in mid-2021, China's biotech and biopharma sectors have followed global trends and cooled off. But are China-based assets still attracting long-term growth investors?

Join Bloomberg Intelligence and leaders from across China's healthcare funding spectrum as they share expert insights on what we can expect for Chinese biotech and biopharma in the year ahead, including:
  • If we should expect a shift to new sub-sectors such as new therapeutic platforms, AI and tech-based services
  • Whether valuations have bottomed-out or we're likely to see a near-term rebound
  • The risks of official policy changes

Speakers

Andrew Ng

Managing Director

VMS Group

Andrew Ng, MBA is a Managing Director of VMS Group, a multi-strategies investment group with AUM around US$ 3 billion based in Hong Kong with diversified businesses covering proprietary investments, structured finance, asset management, securities brokerage and corporate finance advisory, where he is responsible for its healthcare investment practice. Prior to VMS Group, Andrew was the Head of China Healthcare Equity Research at Barclays Capital. Before that, he was an investment banker at Barclays focusing on cross-border healthcare M&A and a management consultant at ZS Associate in the United States advising global big pharma on sales & marketing strategy and operations. Andrew received an MBA from INSEAD and holds a MEng degree and a B.S. degree in Operations Research & Engineering from Cornell University.

Lisa Cai

Director

Nan Fung Life Sciences

Lisa Cai, MBA is a Director at Nan Fung Life Sciences, part of Nan Fung Group, a global investment platform focusing on life sciences. Prior to NFLS, Lisa was a senior research analyst at NF Trinity, Nan Fung Group’s financial investment arm, where she was responsible for the fund’s publicly listed investments in the global healthcare sector. Prior to NF Trinity, Lisa was a senior analyst at Agamemnon Capital, a global event-driven hedge fund, where she focused on the healthcare sector. She was also an Assistant Vice President at SAFE, the Chinese sovereign wealth fund, managing its global healthcare holdings. She started her career in private equity with Morgan Stanley in San Francisco. Lisa earned her MBA from The Wharton School at University of Pennsylvania, and her Bachelor of Science and Bachelor of Arts degrees from University of California, Berkeley.

Steve Wang

Partner

Davis Polk & Wardwell

Steve Wang, PhD, is a partner at Davis Polk & Wardwell where he advises and represents issuers and underwriters in international capital markets transactions, including initial public offerings and follow-on equity offerings, investment-grade and high-yield debt offerings, and liability management transactions. He also advises clients ranging from early-stage privately held companies to public companies on corporate governance, securities law compliance, strategic transactions and other corporate law matters. Dr. Wang focuses on biotech and healthcare companies though his practice also spans a variety of other industries, including technology, consumer and retail, and real estate. He holds a PhD in cell biology and Doctor of Law from the University of Minnesota. He was named in the Rising Star list at the 2020 International Financial Law Review Asia-Pacific Awards.

Mia He

Senior Analyst, APAC Biotech & Pharma

Bloomberg

Mia He, MD, MBA is a senior analyst with Bloomberg Intelligence, covering APAC biotech, pharmaceuticals and health-care services. Dr. He has over 10 years of experience in the healthcare industry and buy-side investment. She joined Bloomberg Intelligence from China Resources Capital as the co-founder of the Life-Sciences Fund and previously worked with CDH Investment, focusing on China's health care primary market. Prior to this, she worked for Sanofi in R&D and the Vanderbilt-Ingram Cancer Center.

Jamie Maarten

Associate Analyst, Asia Health Care

Bloomberg Intelligence

Jamie joined Bloomberg Intelligence's equity team as the Asia Health-Care Associate in 2018. Before joining Bloomberg, Jamie worked in investor relations for early and mid-stage pharmaceutical and biotech companies and managed research projects for institution investors focused on the health-care space. She holds a Bachelors from Columbia University.

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.